Open AccessCD19 signalling improves the Epstein–Barr virus‐induced immortalization of human B cell
Author(s) -
Hur D. Y.,
Lee M. H.,
Kim J. W.,
Kim J.H.,
Shin Y. K.,
Rho J. K.,
Kwack K. B.,
Lee W. J.,
Han B. G.
Publication year - 2005
Publication title -
cell proliferation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.647
H-Index - 74
eISSN - 1365-2184
pISSN - 0960-7722
DOI - 10.1111/j.1365-2184.2005.00328.x
Subject(s) - cd19 , breakpoint cluster region , epstein–barr virus , biology , intracellular , virus , ligation , b cell , virology , cell , cell culture , microbiology and biotechnology , gene , immunology , genetics , antibody
. Epstein–Barr virus (EBV) infection in vitro immortalizes primary B cells and generates B lymphoblastoid cell lines (LCLs). These EBV‐LCLs have been used for several purposes in immunological and genetic studies, but some trials involving these transformations fail for unknown reasons, and several EBV‐LCLs do not grow in normal culture. In this study, we improved the immortalization method by CD19 and B‐cell receptor (BCR) co‐ligation. This method shortens the time required for the immortalization and generation of EBV‐LCLs but does not alter the cell phenotype of the LCLs nor the expression of the EBV genes. In particular, the CD19 and BCR co‐ligation method was found to be the most effective method examined. EBV‐infected B cells induced by CD19 and/or BCR ligation expressed the intracellular latent membrane protein LMP‐1 earlier than EBV‐infected B cells, and the expression of intracellular LMP‐1 was found to be closely related to the time of immortalization. These results suggest that the modified method, using CD19 and/or BCR ligation, may efficiently generate EBV‐LCLs, by expressing intracellular LMP‐1 at an early stage.